Where does Cantargia AB rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cantargia AB ranks #15,883 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cantargia AB hold?

Cantargia AB holds 18 US utility patents granted between 2016 and 2025, spanning 11 technology areas.

What is Cantargia AB's Innovation Score?

Cantargia AB has an Innovation Score of 39.7 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cantargia AB focus on?

Cantargia AB's top technology area is C07K (Peptides) with 18 patents, ranking #536 of 3,615 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Cantargia AB's patent grant rate increasing or decreasing?

Cantargia AB's recent grant velocity is +29% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Cantargia AB's patents?

Cantargia AB's patents average 18.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cantargia AB patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cantargia AB

USPTO PatentsView assignee record - 18 granted patents across 11 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cantargia ranks #15,883 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 11 technology areas.

#15,883
of 49,997 US assignees by volume: Top 37%
by Innovation Score (39.7/100): 18.6
avg claims per patent: +29%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15883 · Foreign Corporation #15,883 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 18 grants
MID-PACK #15,883/49,997
PHOTO-FINISH Calnetix
CPC-FOCUS C07K · 11 areas
INNOV-THIN 39.7/100
CLAIMS-RICH 18.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +29% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Calnetix Technologies, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cantargia’s 39.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (26%) Velocity 6.7 pts (17%) Breadth 11.7 pts (29%) Claim depth 11.2 pts (28%)

Qualcomm Incorporated · highest

85
Cantargia AB · this assignee

40
3D Lighting… · lowest

7

What this shows Cantargia's Innovation Score is 39.7/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cantargia?

Each dot is one of Cantargia’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cantargia’s own 18.6 claims/patent is ABOVE the 15.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cantargia vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cantargia's grants concentrate

Cantargia AB is a focused PatentsView assignee: 11 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2018 (3 grants) versus a trough of 1 in 2017. By volume, Cantargia sits between CV6 Therapeutics (NI) Limited and Century Plastics, LLC.

Cantargia's three-year grant acceleration

Cantargia AB shows 5 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

CV6 Therapeutics…

18
Cyvek

18
Calnetix

18
Canaan Creative

18
Cardiva Medical

18
Carl Geringhoff &…

18
Catalent U K Swin…

18
Century Plastics

18
Cantargia AB ◀

18

What this shows Cantargia holds 18 patents at rank #15,914, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cantargia

By rank, the assignees closest to #15,914 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Cantargia's primary technology class.

Cantargia's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Cantargia AB patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	11.1%
2017	1	5.6%
2018	3	16.7%
2019	1	5.6%
2020	3	16.7%
2021	1	5.6%
2022	3	16.7%
2023	1	5.6%
2024	1	5.6%
2025partial year	2	11.1%

Which technologies does Cantargia AB patent most?

C07K - Peptides 18

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 17

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 11

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

G06Q - Information AND Communication Technology [ICT] Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory PURPOSES; Systems OR Methods Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory Purposes, NOT Otherwise Provided FOR 3

H04W - Wireless Communication Networks 3

G01C - Measuring Distances, Levels OR BEARINGS; SURVEYING; NAVIGATION; Gyroscopic INSTRUMENTS; Photogrammetry OR Videogrammetry 3

G08G - Traffic Control Systems 3

H04M - Telephonic Communication 3

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cantargia AB's patent record in context - here's where to go next.

Cantargia AB's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #15,883 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cantargia AB against CV6 Therapeutics (NI) Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.